H
Hong Liu
Researcher at Shandong University
Publications - 2349
Citations - 79103
Hong Liu is an academic researcher from Shandong University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 100, co-authored 1905 publications receiving 57561 citations. Previous affiliations of Hong Liu include Shanghai University & Guangzhou University.
Papers
More filters
Journal ArticleDOI
Molecular Characterization of a Novel ortho-Nitrophenol Catabolic Gene Cluster in Alcaligenes sp. Strain NyZ215
TL;DR: Alcaligenes sp.
Journal ArticleDOI
General Approach to the Synthesis of Heterodimers of Metal Nanoparticles through Site-Selected Protection and Growth.
TL;DR: This work demonstrates a general approach to the fabrication of hetero-dimers of metal nanoparticles by leveraging the concept of site-selected growth under the protection of an inert material, and prepares Au-Ag, Au-pd, and Au-Pt hetero -dimers and further investigated their plasmonic properties.
Journal ArticleDOI
Copper(I)-catalyzed one-pot synthesis of 2H-1,4-benzoxazin-3-(4H)-ones from o-halophenols and 2-chloroacetamides.
TL;DR: In this paper, the authors developed an efficient and convenient method for preparing N-substituted 2H-1,4-benzoxazin-3-(4H)-ones from 2-halophenols via a nucleophilic substitution with 2-chloroacetamides followed by a CuI-catalyzed coupling cyclization.
Journal ArticleDOI
Activation of mTORC1 disrupted LDL receptor pathway: a potential new mechanism for the progression of non-alcoholic fatty liver disease.
Jing Liu,Kun Ling Ma,Yang Zhang,Yu Wu,Ze Bo Hu,Lin Li Lv,Ri Ning Tang,Hong Liu,Xiong Z. Ruan,Bi Cheng Liu +9 more
TL;DR: Results demonstrated that inflammation increased lipid accumulation in HepG2 cells and in livers of apolipoprotein E knockout mice and down-regulated the expression of proprotein convertase subtilisin kexin 9 (PCSK9) and prevented the degradation of LDLR protein via posttranscriptional mechanisms.
Journal ArticleDOI
Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy.
Hong Liu,Zhenzhen Wang,Fangfang Bao,Chuan Wang,Lele Sun,Huimin Zhang,Gongqi Yu,Zihao Mi,Li Jx,Lulu Li,Qing Zhao,Zhenhua Yue,Wei Zhao,Wenjun Yu,Jing Cao,Fei Xiong,Yaru Wang,Zemin Chai,Xiujun Cheng,Yuan Zhang,Fanghui Fu,Xiaoqiao Lang,Xiaoling Wang,Astrid Irwanto,Hana Krismawati,Xi'an Fu,Yonghu Sun,Jiabao You,Jian Liu,Qing Pan,Tongsheng Chu,Dianchang Liu,Shumin Chen,Jianping Shen,Liangbin Yan,Guocheng Zhang,Jianjun Liu,Furen Zhang,Li Xiong,Jun Yang,Jinlan Li,Wei Ke,Ming Li,Yong Ning,Junhao Xiong,Mingzhou Xiong,Bin Yang,Qizhi Duan,Hong Wang,Wei Li,Yanfei Kuang,Junhua Li,Lamei Wang,Qiuyang Cao,Peng Xiao,Bangzhong Xiao,Lianhua Zhang,Zhaoxing Lin,Yaofei Wang,Yunliang Shen,Liying Yan,Wenbin Wu,Hu Zheng,Xianfa Zhan,Wanghua Li,Xiujian Shang,Yujun Xu,Qiao Liu +67 more
TL;DR: Prospective HLA-B*13:01 screening and subsequent elimination of dapsone from MDT for patients with HLA’s 13:01-positive leprosy may significantly reduce the incidence of DHS in the Chinese population.